Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Cash (2016 - 2025)

Altimmune (ALT) has disclosed Change in Cash for 16 consecutive years, with -$121.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 375.07% to -$121.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $29.8 million, a 153.74% increase, with the full-year FY2024 number at -$98.2 million, down 508.67% from a year prior.
  • Change in Cash was -$121.9 million for Q3 2025 at Altimmune, down from $134.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $134.0 million in Q2 2025 to a low of -$121.9 million in Q3 2025.
  • A 5-year average of -$2.9 million and a median of -$6.4 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: soared 1370.9% in 2021, then tumbled 1202.89% in 2022.
  • Altimmune's Change in Cash stood at $15.4 million in 2021, then crashed by 206.03% to -$16.4 million in 2022, then surged by 394.86% to $48.3 million in 2023, then tumbled by 88.7% to $5.5 million in 2024, then crashed by 2335.31% to -$121.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Change in Cash are -$121.9 million (Q3 2025), $134.0 million (Q2 2025), and $12.2 million (Q1 2025).